QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)

Boston Scientific Stock Price, News & Analysis (NYSE:BSX)

$54.82
-0.06 (-0.11%)
(As of 12/6/2023 ET)
Compare
Today's Range
$54.31
$55.22
50-Day Range
$48.64
$56.14
52-Week Range
$44.35
$56.22
Volume
4.44 million shs
Average Volume
8.04 million shs
Market Capitalization
$80.31 billion
P/E Ratio
66.85
Dividend Yield
N/A
Price Target
$60.70

Boston Scientific MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
10.7% Upside
$60.70 Price Target
Short Interest
Healthy
0.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.02
Upright™ Environmental Score
News Sentiment
1.32mentions of Boston Scientific in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$20.05 M Sold Last Quarter
Proj. Earnings Growth
10.95%
From $2.01 to $2.23 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.81 out of 5 stars

Medical Sector

57th out of 957 stocks

Surgical & Medical Instruments Industry

11th out of 78 stocks


BSX stock logo

About Boston Scientific Stock (NYSE:BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

BSX Stock Price History

BSX Stock News Headlines

Boston Scientific (NYSE:BSX) Price Target Raised to $61.00
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Boston Scientific Closes Acquisition Of Relievant Medsystems
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
See More Headlines
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/26/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/07/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
10113710
Employees
45,000
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$60.70
High Stock Price Target
$66.00
Low Stock Price Target
$55.00
Potential Upside/Downside
+10.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
16 Analysts

Profitability

Net Income
$698 million
Pretax Margin
13.63%

Debt

Sales & Book Value

Annual Sales
$12.68 billion
Cash Flow
$2.54 per share
Book Value
$12.27 per share

Miscellaneous

Outstanding Shares
1,464,980,000
Free Float
1,457,219,000
Market Cap
$80.31 billion
Optionable
Optionable
Beta
0.78

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Boston Scientific was last updated on Wednesday, November 29, 2023 at 8:52 AM.

Pros

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

  • Boston Scientific Corporation is a well-established company that has been in operation since 1979.
  • They develop, manufacture, and market medical devices for various interventional medical specialties worldwide.
  • The company offers a wide range of products, including stents, pacemakers, and catheters, which are in high demand in the healthcare industry.
  • Boston Scientific has a strong track record of innovation and regularly introduces new and advanced medical devices to the market.
  • Investing in Boston Scientific Co. provides an opportunity to be part of the growing healthcare industry, which is expected to continue expanding in the future.

Cons

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

  • While Boston Scientific has a strong presence in the medical device industry, it faces competition from other established companies in the market.
  • The healthcare industry is subject to regulatory changes and uncertainties, which could impact the demand for medical devices and the company's financial performance.
  • Investing in medical device companies can be risky, as the success of new products and technologies is not guaranteed.
  • The stock price of Boston Scientific Co. may be influenced by market fluctuations and investor sentiment, which can result in volatility.
  • It is important for investors to carefully analyze the financial performance and growth prospects of Boston Scientific Co. before making investment decisions.














BSX Stock Analysis - Frequently Asked Questions

Should I buy or sell Boston Scientific stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 1 hold rating, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BSX shares.
View BSX analyst ratings
or view top-rated stocks.

What is Boston Scientific's stock price target for 2024?

16 brokerages have issued 1 year price targets for Boston Scientific's stock. Their BSX share price targets range from $55.00 to $66.00. On average, they anticipate the company's stock price to reach $60.70 in the next twelve months. This suggests a possible upside of 10.7% from the stock's current price.
View analysts price targets for BSX
or view top-rated stocks among Wall Street analysts.

How have BSX shares performed in 2023?

Boston Scientific's stock was trading at $46.27 at the beginning of 2023. Since then, BSX stock has increased by 18.5% and is now trading at $54.82.
View the best growth stocks for 2023 here
.

Are investors shorting Boston Scientific?

Boston Scientific saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 11,850,000 shares, an increase of 29.6% from the October 31st total of 9,140,000 shares. Based on an average trading volume of 8,450,000 shares, the days-to-cover ratio is currently 1.4 days.
View Boston Scientific's Short Interest
.

When is Boston Scientific's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 7th 2024.
View our BSX earnings forecast
.

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) announced its earnings results on Thursday, October, 26th. The medical equipment provider reported $0.50 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.02. The medical equipment provider had revenue of $3.53 billion for the quarter, compared to analysts' expectations of $3.48 billion. Boston Scientific had a trailing twelve-month return on equity of 15.46% and a net margin of 8.93%. The business's revenue was up 11.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.43 earnings per share.
Read the conference call transcript
.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific issued an update on its fourth quarter earnings guidance on Thursday, October, 26th. The company provided earnings per share (EPS) guidance of $0.49-0.52 for the period, compared to the consensus earnings per share estimate of $0.52.

What is Michael F. Mahoney's approval rating as Boston Scientific's CEO?

947 employees have rated Boston Scientific Chief Executive Officer Michael F. Mahoney on Glassdoor.com. Michael F. Mahoney has an approval rating of 98% among the company's employees. This puts Michael F. Mahoney in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), CVS Health (CVS), Walt Disney (DIS), Bank of America (BAC), Advanced Micro Devices (AMD), Visa (V) and Salesforce (CRM).

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (8.60%), Massachusetts Financial Services Co. MA (4.27%), Wellington Management Group LLP (2.87%), Primecap Management Co. CA (2.55%), Morgan Stanley (1.45%) and Artisan Partners Limited Partnership (1.22%). Insiders that own company stock include Arthur C Butcher, Charles J Dockendorff, Daniel J Brennan, David A Pierce, David A Pierce, David S Wichmann, Edward F Mackey, Eric Francis Yves Thepaut, Ian T Meredith, Jeffrey B Mirviss, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Jonathan Monson, Joseph Michael Fitzgerald, Maulik Nanavaty, Meghan Scanlon, Michael F Mahoney, Michael F Mahoney, Nelda J Connors, Scott Olson, Vance R Brown, Wendy Carruthers and William F Bruss.
View institutional ownership trends
.

How do I buy shares of Boston Scientific?

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Boston Scientific have any subsidiaries?
The following companies are subsidiares of Boston Scientific: 34 Biomedical Merger Corp., 9357-1867 Quebec Inc., Acurate Industria e Comercio Ltda., Advanced Bionics, Advanced Stent Technologies, American Medical Systems, American Medical Systems Europe B.V., Apama Medical, Apama Medical Inc., Asthmatx, Atritech, Augmenix, Augmenix Inc., Augmenix K.K., BSC International Medical Trading (Shanghai) Co. Ltd., BSC Medical Device Technology (Shanghai) Co. Ltd., BTG, BTG Australasia Pty Ltd, BTG Europe B.V., BTG IM Holdings Ltd., BTG International (Holdings) Limited, BTG International Asia Limited, BTG International Canada Inc., BTG International Germany GmbH, BTG International Healthcare Inc., BTG International Healthcare LLC, BTG International Healthcare Limited, BTG International Inc., BTG International Limited, BTG Limited, BTG Management Services Limited, BTG Medikal Limited Sirketi, Bard Electrophysiology, Barosense, Biocompatibles Inc., Biocompatibles International Limited, Biocompatibles UK Limited, Boston Scientific (Malaysia) Sdn. Bhd., Boston Scientific (South Africa) Proprietary Limited, Boston Scientific (Thailand) Ltd., Boston Scientific (UK) Limited, Boston Scientific AG, Boston Scientific Argentina S.A., Boston Scientific Asia Pacific Pte. Ltd., Boston Scientific Benelux NV, Boston Scientific Canada Limited, Boston Scientific Ceska republika s.r.o., Boston Scientific Chile SpA, Boston Scientific Colombia Limitada, Boston Scientific Comercial de Costa Rica BSCR S.R.L., Boston Scientific Far East B.V., Boston Scientific Gesellschaft m.b.H., Boston Scientific Group plc, Boston Scientific Hellas S.A., Boston Scientific Hong Kong Limited, Boston Scientific Iberica S.A., Boston Scientific India Private Limited, Boston Scientific International B.V., Boston Scientific International Finance Limited, Boston Scientific International S.A., Boston Scientific Israel Ltd., Boston Scientific Japan K.K., Boston Scientific Korea Co. Ltd., Boston Scientific Lebanon SAL, Boston Scientific Limited, Boston Scientific Ltd., Boston Scientific Medical Device, Boston Scientific Medical Device Limited, Boston Scientific Medizintechnik GmbH, Boston Scientific Middle East FZ-LLC, Boston Scientific Middle East SAL, Boston Scientific Nederland B.V., Boston Scientific Neuromodulation Corporation, Boston Scientific New Zealand Limited, Boston Scientific Nordic AB, Boston Scientific Peru S.A.C., Boston Scientific Philippines Inc., Boston Scientific Polska Sp. z o.o., Boston Scientific Portugal - Dispositivos Medicos Lda, Boston Scientific Pty Ltd, Boston Scientific Romania S.R.L., Boston Scientific S.A.S., Boston Scientific S.p.A., Boston Scientific Scimed, Boston Scientific Scimed Inc., Boston Scientific Services Private Limited, Boston Scientific TIP Gerecleri Limited Sirketi, Boston Scientific Technology & Engineering Services Private Limited, Boston Scientific Uruguay S.A., Boston Scientific Vietnam Company Limited, Boston Scientific de Costa Rica S.R.L., Boston Scientific de Mexico S.A. de C.V., Boston Scientific del Caribe Inc., Boston Scientific do Brasil Ltda., Bravo Bidco Limited, BridgePoint Medical, Cameron Health, Cardiac Pacemakers Inc., Cardiac Pathways Corp, Catheter Innovations, Claret Medical, Claret Medical Inc., Cosman Medical, Cosman Medical LLC, CryoCor, Cryterion Medical, Cryterion Medical Inc., Cryterion Medical Ireland Limited, EKOS LLC, EMcision, EMcision International Inc., EP Technologies, EP Technologies Inc., Electron Acquisition Corporation, EndoChoice, EndoChoice Holdings Inc., EndoChoice Inc., EndoChoice Innovation Center Ltd., EndoChoice Israel Ltd., Endotex, Enteric Medical Technologies, Galil Medical Inc., Galil Medical Ltd., Galil Medical UK Limited, Guidant, Guidant Delaware Holding Corporation, Guidant Europe NV, Guidant Puerto Rico B.V., Hong Kong Medtech Trading Limited, Intelect Medical, Millipede, Millipede Inc., NXT Merger Corp., Notebook Merger Sub Ltd., Novate Medical Limited, NxThera, NxThera Inc., PT Boston Scientific Indonesia, PneumRx GmbH, PneumRx LLC, PneumRx Liimited, Protherics Medicines Development B.V., Protherics Medicines Development Limited, Protherics UK Limited, Provensis Limited, RMI Acquisition Corp., Remon Medical Technologies, Rhythmia Medical, Robert S. Smith M.D. Inc., Roxwood Medical Inc., SNS Merger Corp, Sadra Medical, Sadra Medical Inc., Securus Medical Group, Securus Medical Group Inc., Special K Merger Corp., StarMedTec, Stream Enterprises LLC, Symetis, Symetis SA, Target Therapeutics, Target Therapeutics Inc., The LumenR Tissue Retractor System, Veniti, Veniti Inc., VertiFlex, Vertiflex Inc., Vessix Vascular, Xlumena, Zuma Investment Pty Ltd, iogyn, nVision Medical, and nVision Medical Corporation.
Read More
This page (NYSE:BSX) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -